| TA144 |
Obesity - rimonabant (withdrawn) (TA144) |
|
-
-
Rimonabant for the treatment of overweight and obese patients
The European Medicines Agency (EMEA), the European Union (EU) body which is responsible for monitoring the safety of medicines, has recommended the suspension of the marketing authorisation for rimonabant (acomplia) from Sanofi-Aventis. The EMEA has concluded that the benefits of rimonabant no longer outweigh its risks and the marketing authorisation should be suspended across the EU. The EMEA has advised that patients who are currently taking rimonabant should consult their doctor or pharmacist at a convenient time to discuss their treatment. The EMEA has advised that there is no need for patients to stop treatment with rimonabant immediately, but patients who wish to stop can do so at any time.
As a result of the EMEA's decision, NICE has temporarily withdrawn its guidance on the use of rimonabant for the treatment of overweight and obese patients.
Further information on the EMEA's decision is available from its website.
We will consult on our review plans for this guidance in April 2010.
-
Other information
How this guidance was produced
Background information
This page was last updated: 30 March 2010
-
Guidance formats
-
Implementation tools and resources
- None available
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
